Clinical Trial Update: MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of MGCD0103 in combination with azacitidine (Vidaza) for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• MGCD0103 (mocetinostat)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma) | Phase 2 | Status: TERMINATED